Categories
Change Password!
Reset Password!
Physicians can recommend naloxone 8 mg nasal spray in patients suffering from opioid overdose.
A higher dose naloxone hydrochloride nasal spray (8 mg)
for the treatment of opioid overdose has now been sanctioned by the FDA, as
announced on April 30, 2021.This nasal spray has already been approved in 2 and
4 mg dosages (in the year 2015).
This opioid-receptor antagonist can
be administered with or without medical training can help decrease the deaths
due to opioid overdose. A rapid use of this nasal spray can neutralize the
opioid overdose effects, typically in minutes.
“Focusing on
the opioid crisis is of utmost importance to the FDA, and efforts to escalate
access to naloxone
and place this medicine in the needful can help tackle opioid overdose,”
mentioned the M.D. of the
FDA’s Center for Drug Evaluation and Research (CDER).
After the approval of naloxone in 1971 for the
treatment of opioid overdose, FDA has taken a numerous
steps to improve accessibility of naloxone products, i.e: encouraging the companies
to follow authorization of over-the-counter naloxone products; requiring
pharmaceuticals for all opioid analgesics to add naloxone’s latest recommendations to the
prescribing information; and prolonging its shelf life from 2 years to 3 years.
Application of naloxone in opioid-dependent patients
may lead to opioid withdrawal depicted by body pains, diarrhea, tachycardia,
runny nose, fever, sneezing, piloerection, sweating, yawning, nausea or
vomiting, nervousness, restlessness or irritability, shivering or trembling,
abdominal pain, weakness and high BP.
FDA
FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose
Comments (0)